Trial reportThe American journal of drug and alcohol abuse2011
The association between naltrexone treatment and symptoms of depression in opioid-dependent patients.
Trial report in The American journal of drug and alcohol abuse, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Treatment interventions for co-occurring opioid use disorder, and sleep disturbances: a scoping review.Substance abuse treatment, prevention, and policy · 2026Pooled it
- Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone.The American journal of drug and alcohol abuse · 2025Trial
- Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale.Journal of affective disorders · 2022Trial
- Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.Substance use & misuse · 2022Trial
- Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.Addiction (Abingdon, England) · 2020Trial
- Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.JAMA psychiatry · 2019Trial
- Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.Drug and alcohol dependence · 2018Trial
- Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.The American journal of drug and alcohol abuse · 2016Trial
- Baseline characteristics of patients predicting suitability for rapid naltrexone induction.The American journal on addictions · 2015Trial
- Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.The American journal on addictions · 2023Article
- Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.Psychopharmacology · 2022Article
- Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders.Current addiction reports · 2021Review
- Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?Neuronal signaling · 2018Review
- Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.The American journal on addictions · 2018Review
- Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.The American journal on addictions · 2017Article
- Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.Psychopharmacology · 2015Article
- Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.Journal of psychopharmacology (Oxford, England) · 2015Article
- Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.Substance abuse and rehabilitation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo examine the change in total symptoms, and symptom clusters, of depression in newly abstinent opioid-dependent individuals being treated with depot naltrexone (Depotrex; Biotek, Inc., Wellesley, MA).
methodIn a series of opioid-dependent patients (N = 34) treated with naltrexone maintenance and relapse prevention therapy, mood was assessed with a 17-item Hamilton Depression (HAM-D) Scale and subscale scores at baseline, and after naltrexone induction at 2- and 4-week post-baseline. Data were analyzed using generalized estimated equation (GEE) models.
resultsPatients demonstrated high baseline affective burden and significant improvement of depression scores over a 4-week period post-baseline (F(2.66) = 8.88; p = .0004). Somatic and cognitive-affective subscale scores significantly declined as well as the seven individual item scores. By contrast, the "late insomnia" item score significantly increased at 2 weeks post-baseline. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Naltrexone induction and maintenance in newly abstinent opioid-dependent individuals does not appear to be associated with worsening of depression; however, it may be associated with sleep impairment early in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.